Investor Presentation First Nine Months of 2022
54
Investor presentation First nine months of 2022
ONWARDS 2 met its primary endpoint and demonstrated
superiority on HbA₁c reduction compared to insulin degludec
Superior change in HbA1c from baseline over time 26 weeks
Time since randomisation (weeks)
10
18
•
26
26*
Inclusion criteria:
•
T2D treated with basal insulin + OADs* ± GLP-1 s.c.
Age ≥18 years, HbA1c 7-10%, BMI ≤ 40 kg/m2
Change from baseline (%)
0.0
-0.4
-0.8
ΚΗ
HHHH
-0.71%
Novo NordiskⓇ
•
Endpoints:
Once-weekly insulin icodec achieved a superior reduction in
estimated HbA1c compared to insulin degludec (ETD: -0.22%)
ONWARDS 2 showed a statistically significant improvement in
quality of life compared to insulin degludec
-1.2
=
-0.93%
Once-weekly insulin icodec Once-daily insulin degludec
Note: Overall baseline HbA1c
of 8.13%
Safety:
•
No statistically significant difference in estimated rates of severe
or clinically significant hypoglycaemia events
In the trial, once-weekly insulin icodec appeared to have a safe
and well-tolerated profile
*Lines are based on observed data where the value denoted after 26 weeks is estimated mean value derived based on multiple imputation
ETD: Estimate treatment differenceView entire presentation